Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00666276 |
Drug use investigation of Zyvox for patients with Methicillin-resistant Staphylococcus aureus (MRSA) infection disease.
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3)factors considered to affect the safety and/or efficacy of this drug.
Condition | Intervention | Phase |
---|---|---|
Staphylococcal Infections |
Drug: Linezolid |
Phase IV |
Study Type: | Observational |
Study Design: | Case-Only, Prospective |
Official Title: | Drug Use Investigation Of Zyvox (Linezolid) (Regulatory Post Marketing Commitment Plan) |
Estimated Enrollment: | 1000 |
Study Start Date: | February 2007 |
Estimated Study Completion Date: | July 2009 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
Linezolid
Patients taking Linezolid.
|
Drug: Linezolid
Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese LPD, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg. Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration. |
All the patients whom an investigator prescribes the first Linezolid should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
The patients whom an investigator involving A5951142 prescribes the Linezolid.
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Pfizer, Inc. ( Director, Clinical Trial Disclosure Group ) |
Study ID Numbers: | A5951142 |
Study First Received: | April 22, 2008 |
Last Updated: | April 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00666276 History of Changes |
Health Authority: | Japan: Pharmaceuticals and Medical Devices Agency (PMDA) |
Bacterial Infections Staphylococcal Infections Gram-Positive Bacterial Infections Linezolid |
Bacterial Infections Protein Synthesis Inhibitors Anti-Infective Agents Staphylococcal Infections Gram-Positive Bacterial Infections Molecular Mechanisms of Pharmacological Action |
Therapeutic Uses Enzyme Inhibitors Infection Linezolid Pharmacologic Actions |